Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
3(100.0%)
3Total
N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04462627Not ApplicableCompleted

Reduction of COVID 19 Transmission to Health Care Professionals

Role: lead

NCT03405688Not ApplicableCompleted

Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors

Role: lead

NCT03405402Not ApplicableCompleted

Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization

Role: lead

NCT03401125Withdrawn

Risk Factors for Allo-immunization in Sickle Cell Disease

Role: lead

All 4 trials loaded